Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-667 in RET-altered Advanced Solid Tumors
CTR20190767Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil in Non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), RET-altered solid tumors, sponsored by Blueprint Medicines. Started May 2019; status: completed.
02
Drugs
fluorouracil
03
Conditions
Non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)RET-altered solid tumors
Beyond the preview
Go deeper on CTR20190767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190767.